Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB(2) harmonization project comparing three NGS panels

BACKGROUND: Tumor mutational burden (TMB) is a recently proposed predictive biomarker for immunotherapy in solid tumors, including non-small cell lung cancer (NSCLC). Available assays for TMB determination differ in horizontal coverage, gene content and algorithms, leading to discrepancies in result...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos-Paradas, Javier, Hernández-Prieto, Susana, Lora, David, Sanchez, Elena, Rosado, Aranzazu, Caniego-Casas, Tamara, Carrizo, Nuria, Enguita, Ana Belén, Muñoz-Jimenez, María Teresa, Rodriguez, Borja, Perez-Gonzalez, Urbicio, Gómez-Sánchez, David, Ferrer, Irene, Ponce Aix, Santiago, Nuñez Buiza, Ángel, Garrido, Pilar, Palacios, José, Lopez-Rios, Fernando, Garrido-Martin, Eva M, Paz-Ares, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108670/
https://www.ncbi.nlm.nih.gov/pubmed/33963008
http://dx.doi.org/10.1136/jitc-2020-001904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108670/
https://www.ncbi.nlm.nih.gov/pubmed/33963008
http://dx.doi.org/10.1136/jitc-2020-001904

Ejemplares similares